Drug intelligence / Profile preview

AERAS-422

Development stage: Phase 1
Lead developer: International AIDS Vaccine Initiative
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

AERAS-422 is a recombinant BCG (rBCG) vaccine derived from the Danish 1331 strain of BCG. It was engineered to overexpress specific TB antigens (**Ag85A**, **Ag85B**, and **Rv3407**) and express a mutant perfringolysin (**PFO G137Q**) from *Clostridium perfringens*. The vaccine was designed for tuberculosis prevention, aiming to improve upon the standard BCG vaccine by using the PFO component to facilitate antigen entry into the cytosol and stimulate an MHC Class I-restricted immune response, potentially generating stronger and more persistent CD8+ T cell responses.

Targets

Ag85B (Antigen 85B)

Beyond the preview

Go deeper on AERAS-422.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AERAS-422.

Explore the full profile